San Francisco-based medical robotics startup Remedy Robotics is in advanced talks to secure a $50 million Series B funding round following its groundbreaking achievement as the world’s first company to successfully complete fully remote endovascular procedures. Founded by CEO Dr. David Bell, a cardiothoracic surgeon, and CTO Jake Sganga, a Stanford-trained PhD in surgical robotics, the company has revolutionized stroke treatment by enabling specialists to perform life-saving procedures remotely using their N1 robotic system.
The funding round comes on the heels of historic milestones achieved in Toronto, where Dr. Vitor Mendes Pereira of St. Michael’s Hospital completed the world’s first entirely remote endovascular interventions using Remedy’s technology. The procedures were conducted both from a room 50 meters down the hall and from a different hospital six miles away, demonstrating the system’s ability to deliver precise medical intervention across distances with just 8 milliseconds of latency.
Previous investors in Remedy Robotics include DCVC, which led the seed round, along with Blackbird, KdT Ventures, and Tony Fadell’s Build Collective. The company has already raised $35 million across seed and Series A rounds, with this latest funding representing significant growth as the company prepares for commercial deployment of its revolutionary technology. DCVC Partner highlighted the critical need, noting that while 270,000 Americans annually require mechanical thrombectomy for stroke treatment, only 30,000 currently receive it due to geographical and specialist availability constraints.
Remedy’s N1 system addresses the fundamental talent distribution problem in stroke care by enabling the world’s best neurosurgeons to treat patients anywhere in real-time. The platform combines proprietary hardware with AI-enabled software to perform endovascular procedures for stroke, heart attack, and vascular trauma, whether across the room or across the globe. This breakthrough technology could potentially transform care for millions of people who currently face death or disability simply because they live too far from specialist hospitals.
The company recently announced a strategic partnership with the Australian Stroke Alliance, a consortium of over 40 government and private sector organizations, which selected Remedy as its exclusive robotics partner to expand access to endovascular thrombectomy across Australia. The partnership aims to address significant disparities in stroke care access, particularly for rural and Indigenous populations, by enabling specialists to perform remote procedures and reduce treatment delays.
Looking ahead, Remedy plans to use the Series B funding to scale manufacturing operations, expand clinical trials, and pursue regulatory approvals in multiple markets including Australia and the United States. The company aims to deploy its technology across approximately 3,500 U.S. hospitals with catheterization labs, dramatically expanding access to life-saving stroke interventions. With plans to eventually treat 30 different cardiovascular conditions using the same platform, Remedy is positioning itself to become a generational company that could save millions of lives worldwide.
